Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Swain

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentS Dawood, S D Merajver, P Viens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancerS M Swain, F S Whaley, M C Gerber, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentS Dawood, S D Merajver, P Viens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancerS M Swain, F S Whaley, M C Gerber, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerR Dent, F André, A Gonçalves, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)A Fernandez-Martinez, M Tanioka, S G Ahn, et al.
Pageof 8